Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."

Recent & Breaking News (NDAQ:OXGN)

OXiGENE, Inc. Announces $12 Million Public Offering

GlobeNewswire February 12, 2014

OXiGENE Announces Presentation at BIO CEO Conference on February 11th

Globe Newswire January 30, 2014

OXiGENE Appoints Frederick W. Driscoll to Its Board of Directors

Globe Newswire November 27, 2013

OXiGENE Announces Preclinical Data Presentation on Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity

Globe Newswire November 18, 2013

OTIV, SIRI, QGEN and OXGN added to NASDAQ Active Stock Watch List at EPR

Accesswire November 18, 2013

OXiGENE to Present Phase I Data Demonstrating Antitumor Activity of OXi4503 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Globe Newswire November 18, 2013

OXiGENE Reports Third Quarter 2013 Financial Results

Globe Newswire November 12, 2013

AGNC, NWSA, OXGN and LXRX added to NASDAQ Active Stock Watch List at GSR

Accesswire November 12, 2013

InvestorsGuru.com 44 Filtered Mid-Day Market Movers Recap

Investors Guru November 10, 2013

TrendingWallStreet.com Initiates Market Analysis on HK, FNMA, GSAT, and OXGN

Accesswire November 7, 2013

OXiGENE Announces Third Quarter 2013 Earnings Conference Call and Webcast

Globe Newswire November 4, 2013

OXiGENE to Present at BIO-Europe Conference on November 6th

Globe Newswire November 4, 2013

OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

Globe Newswire October 21, 2013

OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

Globe Newswire October 15, 2013

OXiGENE to Present at 12th Annual BIO Investor Forum Conference on October 8, 2013

Globe Newswire September 30, 2013

OXiGENE Announces $5.8 Million Private Placement

Globe Newswire September 19, 2013

OXiGENE Announces Presentation at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9th

Globe Newswire September 3, 2013

OXiGENE Reports Second Quarter 2013 Financial Results

Globe Newswire August 6, 2013

OXiGENE Announces Second Quarter 2013 Earnings Conference Call and Webcast

Globe Newswire July 24, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CBST, HOLX, ICUI and OXGN

Accesswire July 22, 2013